Pantoprazol Stada (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazol Stada, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults. GNH USA supplies Pantoprazol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Pantoprazol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Stada is a proton pump inhibitor indicated for acid‑related disorders of the gastrointestinal tract.

- Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief of heartburn and promotes healing of erosive esophagitis. - Erosive esophagitis: accelerates mucosal healing and prevents disease progression. - Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours. - Helicobacter pylori eradication regimens (as part of combination therapy): enhances ulcer healing when used with antibiotics.

Pantoprazol Stada is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea or abdominal discomfort: occasional. - Flatulence: mild bloating. - Constipation: infrequent. - Dry mouth: occasional.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema): require immediate medical attention. - Clostridioides difficile‑associated diarrhea: may be life‑threatening. - Low magnesium levels (hypomagnesemia): can cause muscle cramps or cardiac arrhythmia. - Bone fractures (with long‑term use): increased risk of hip, wrist or spine fractures. - Acute interstitial nephritis: renal impairment requiring monitoring. - Liver enzyme elevations: may indicate hepatic stress.

Before starting Pantoprazol Stada, consider the following safety measures:

- Assess renal function: dose adjustment may be needed in severe impairment. - Review hepatic status: use with caution in moderate to severe liver disease. - Evaluate long‑term use: monitor for bone density loss and magnesium levels. - Pregnancy and lactation: weigh potential benefits against risks; consult a healthcare professional. - Drug interactions: check for concomitant use of drugs that require gastric acidity for absorption. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazol Stada may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption leading to therapeutic failure. - Atazanavir: markedly decreased plasma concentrations, compromising HIV treatment. - Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR; monitor coagulation parameters. - Digoxin: increased serum levels; observe for signs of toxicity. - Methotrexate (high dose): reduced renal clearance; check renal function and drug levels.